ClinicalTrials HQ

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

Recruiting · NCT06922591 · Registry updated 2026-05-14
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsNeoplasms by Site, Thoracic Neoplasms, lung cancer, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, thoracic cancerRecruitingPhase 1 / Phase 22026-05-14NCT06922591

2 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Revolution Medicines, Inc.18
Tango Therapeutics, Inc.5

18 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Dana-Farber Cancer InstituteBostonUnited States68
Georgetown University Medical CenterWashington D.C.United States62
Huntsman Cancer Institute, University of UtahSalt Lake CityUnited States45
Massachusetts General HospitalBostonUnited States1015
Mayo Clinic Cancer CenterRochesterUnited States2
Mayo Clinic JacksonvilleJacksonvilleUnited States67
Mayo Clinic ScottsdaleScottsdaleUnited States2
Memorial Sloan Kettering Cancer CenterNew YorkUnited States3
Nebraska Cancer SpecialistsOmahaUnited States2
NEXT DallasIrvingUnited States1
NEXT OncologyFairfaxUnited States31
Northwestern Memorial HospitalChicagoUnited States4
NYU Langone HealthNew YorkUnited States403
Sarah Cannon Research Institute DenverDenverUnited States1
University of IndianaIndianapolisUnited States2
University of Iowa Health CareIowa CityUnited States47
University of North Carolina at Chapel HillChapel HillUnited States2
University of Texas MD Anderson Cancer CenterHoustonUnited States192